Published in J Oncol on December 15, 2010
Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma. Cancer Prev Res (Phila) (2011) 1.44
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol (2011) 0.93
Emerging roles of p53 in glial cell function in health and disease. Glia (2011) 0.81
Conversion of fibroblasts to neural cells by p53 depletion. Cell Rep (2014) 0.78
dp53 Restrains ectopic neural stem cell formation in the Drosophila brain in a non-apoptotic mechanism involving Archipelago and cyclin E. PLoS One (2011) 0.76
Spontaneous Malignant Transformation of a Pilocytic Astrocytoma of Cerebellum: Case Report. Child Neurol Open (2015) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Malignant gliomas in adults. N Engl J Med (2008) 20.54
Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science (1992) 19.30
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell (1999) 15.87
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell (2009) 12.96
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature (2009) 9.75
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol (1965) 9.18
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature (2009) 8.70
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev (2005) 7.27
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature (2009) 6.85
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell (2009) 6.64
Brain tumour stem cells. Nat Rev Cancer (2006) 5.84
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol (2007) 5.80
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci U S A (1993) 5.00
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet (1993) 3.85
p53 enters the microRNA world. Cancer Cell (2007) 3.78
ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol (1998) 3.77
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 3.54
p53 suppresses the self-renewal of adult neural stem cells. Development (2006) 3.35
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
A subset of p53-deficient embryos exhibit exencephaly. Nat Genet (1995) 3.24
Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 3.22
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev (2005) 3.08
Stem cells: The promises and perils of p53. Nature (2009) 3.01
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (1992) 2.80
Glioma stem cells: a midterm exam. Neuron (2008) 2.69
Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 2.65
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
High-frequency developmental abnormalities in p53-deficient mice. Curr Biol (1995) 2.57
Cancer stem cells--old concepts, new insights. Cell Death Differ (2008) 2.56
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol (2010) 2.45
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 2.31
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene (1993) 2.25
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell (2009) 2.14
Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron (1998) 2.11
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res (2010) 2.07
NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J (2010) 2.01
Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci (2006) 2.00
Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res (1998) 1.99
Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol (2009) 1.98
Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene (2009) 1.96
A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J (2009) 1.95
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res (1994) 1.84
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res (1999) 1.83
Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst (1994) 1.81
Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov (2004) 1.74
p53 suppresses the self-renewal of adult neural stem cells. Development (2006) 3.35
Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. EMBO J (2011) 2.71
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell (2010) 1.91
PDGF and PDGF receptors in glioma. Ups J Med Sci (2012) 1.43
Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro Oncol (2011) 1.16
Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One (2011) 1.16
Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation. PLoS One (2010) 1.16
Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem (2006) 1.13
Transcription factor PROX1: its role in development and cancer. Cancer Metastasis Rev (2012) 1.05
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol (2009) 1.05
Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res (2003) 1.04
Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res (2004) 1.02
GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia (2009) 1.00
p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod Pathol (2005) 0.96
Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas. J Neuropathol Exp Neurol (2010) 0.94
Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation. Nucleic Acids Res (2010) 0.94
Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol (2007) 0.94
Regulation of mitochondrial dynamics: convergences and divergences between yeast and vertebrates. Cell Mol Life Sci (2012) 0.93
Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis. Acta Oncol (2006) 0.92
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro Oncol (2010) 0.92
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer (2011) 0.91
The novel conserved mitochondrial inner-membrane protein MTGM regulates mitochondrial morphology and cell proliferation. J Cell Sci (2009) 0.90
A comparison between stem cells from the adult human brain and from brain tumors. Neurosurgery (2008) 0.89
A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival. Int J Cancer (2013) 0.88
Protein extraction from solid tissue. Methods Mol Biol (2011) 0.86
The mitochondrial elongation factors MIEF1 and MIEF2 exert partially distinct functions in mitochondrial dynamics. Exp Cell Res (2013) 0.86
Forced expression of platelet-derived growth factor B in the mouse cerebellar primordium changes cell migration during midline fusion and causes cerebellar ectopia. Mol Cell Neurosci (2004) 0.86
Explaining the biological activity of transactivation-deficient p53 variants. Nat Genet (2006) 0.85
Platelet-derived growth factor-B and -C and active alpha-receptors in medulloblastoma cells. Biochem Biophys Res Commun (2002) 0.85
Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. PLoS One (2011) 0.85
EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells. Biochem Biophys Res Commun (2013) 0.84
C/EBP is an essential component of PDGFRA transcription in MG-63 cells. Biochem Biophys Res Commun (2004) 0.83
Optimized protein extraction from cryopreserved brain tissue samples. Acta Oncol (2007) 0.83
MUC1 as a Putative Prognostic Marker for Prostate Cancer. Biomark Insights (2008) 0.82
RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. Neuro Oncol (2011) 0.82
GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. PLoS One (2012) 0.81
Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol (2006) 0.81
A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett (2002) 0.80
mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels. Cancer Biol Ther (2014) 0.79
Molecular cloning and characterization of two novel truncated isoforms of human Na+/Ca2+ exchanger 3, expressed in fetal brain. Gene (2005) 0.79
Oligodendrocyte precursor hypercellularity and abnormal retina development in mice overexpressing PDGF-B in myelinating tracts. Glia (2003) 0.79
p16INK4a and laminin-5gamma2 chain expression during the progression of cervical neoplasia. Acta Oncol (2006) 0.78
Uncoupling of the ERα regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. Biochem Biophys Res Commun (2011) 0.78
DLG3/SAP102 protein expression in malformations of cortical development: a study of human epileptic cortex by tissue microarray. Epilepsy Res (2009) 0.77
Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol (2007) 0.77
Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling. J Neurooncol (2011) 0.76
Clonality analysis of synchronous lesions of cervical carcinoma based on X chromosome inactivation polymorphism, human papillomavirus type 16 genome mutations, and loss of heterozygosity. J Exp Med (2002) 0.76
Gli1 is not required for Pdgfralpha expression during mouse embryonic development. Differentiation (2005) 0.76
Blood plasma handling for protein analysis. Methods Mol Biol (2011) 0.76
TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor. Biochem Biophys Res Commun (2002) 0.75
Identification and expression analysis of an N-terminally truncated isoform of human PDGF-C. Exp Cell Res (2008) 0.75
Handling of solid brain tumor tissue for protein analysis. Methods Mol Biol (2011) 0.75